A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Study Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

Conditions

SLE (Systemic Lupus)Lupus Erythematosus, Systemic Lupus Nephritis Systemic Sclerosis Inflammatory Myopathy, Idiopathic Myositis Diffuse Cutaneous Systemic Sclerosis

Interventions / Drugs

CTX112

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment80 participants

Primary Completion—

Lead SponsorCRISPR Therapeutics

Data Retrieved2026-04-11 04:10:52.767972+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.